TY - JOUR
T1 - Multilocus phylogeny and antifungal susceptibility of aspergillus section circumdati from clinical samples and description of A. Pseudosclerotiorum sp. Nov.
AU - Siqueira, J. P.Z.
AU - Sutton, D. A.
AU - Gené, J.
AU - García, D.
AU - Wiederhold, N.
AU - Peterson, S. W.
AU - Guarro, J.
N1 - Publisher Copyright:
© Copyright 2017 American Society for Microbiology. All Rights Reserved.
PY - 2017/3
Y1 - 2017/3
N2 - A multilocus phylogenetic study was carried out to assess species identity of a set of 34 clinical isolates from Aspergillus section Circumdati from the United States and to determine their in vitro antifungal susceptibility against eight antifungal drugs. The genetic markers used were the internal transcribed spacer (ITS) region, and fragments of the beta-Tubulin (BenA), calmodulin (CaM), and RNA polymerase II second largest subunit (RPB2) genes. The drugs tested were amphotericin B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, and terbinafine. The most common species sampled was A. westerdijkiae (29.4%), followed by a novel species, which was described here as A. pseudosclerotiorum (23.5%). Other species identified were A. sclerotiorum (17.6%), A. ochraceus (8.8%), A. subramanianii (8.8%), and A. insulicola and A. ochraceopetaliformis, with two isolates (5.9%) of each. The drugs that showed the most potent activity were caspofungin, micafungin, and terbinafine, while amphotericin B showed the least activity.
AB - A multilocus phylogenetic study was carried out to assess species identity of a set of 34 clinical isolates from Aspergillus section Circumdati from the United States and to determine their in vitro antifungal susceptibility against eight antifungal drugs. The genetic markers used were the internal transcribed spacer (ITS) region, and fragments of the beta-Tubulin (BenA), calmodulin (CaM), and RNA polymerase II second largest subunit (RPB2) genes. The drugs tested were amphotericin B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, and terbinafine. The most common species sampled was A. westerdijkiae (29.4%), followed by a novel species, which was described here as A. pseudosclerotiorum (23.5%). Other species identified were A. sclerotiorum (17.6%), A. ochraceus (8.8%), A. subramanianii (8.8%), and A. insulicola and A. ochraceopetaliformis, with two isolates (5.9%) of each. The drugs that showed the most potent activity were caspofungin, micafungin, and terbinafine, while amphotericin B showed the least activity.
KW - Aspergillus
KW - Circumdati section
KW - Clinical isolates
KW - Molecular identification
KW - Phenotypic identification
UR - http://www.scopus.com/inward/record.url?scp=85014405215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014405215&partnerID=8YFLogxK
U2 - 10.1128/JCM.02012-16
DO - 10.1128/JCM.02012-16
M3 - Article
C2 - 28053212
AN - SCOPUS:85014405215
SN - 0095-1137
VL - 55
SP - 947
EP - 958
JO - Journal of clinical microbiology
JF - Journal of clinical microbiology
IS - 3
ER -